Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases

Ruth Webster; Adrianna Murphy; Helen Bygrave; Éimhín Ansbro; Diederick E. Grobbee; Pablo Perel

doi:10.5334/gh.860

Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases

Global Heart

Volume 15 (2020): Issue 1

By: Ruth Webster, Adrianna Murphy, Helen Bygrave, Éimhín Ansbro, Diederick E. Grobbee and Pablo Perel

Open Access

|Aug 2020

Abstract

Highlights:

Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.
A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.
The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.
Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.
Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.

References

World Health Organisation. Global action plan for the prevention and control of non-communicable diseases. Geneva: World Health Organization; 2013.
Search in Google Scholar Back to article
Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet. 2016; 387(10013): 61–9. DOI: 10.1016/S0140-6736(15)00469-9
Open DOI Search in Google Scholar Back to article
Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet. 2011; 378(9798): 1231–43. DOI: 10.1016/S0140-6736(11)61215-4
Open DOI Search in Google Scholar Back to article
Webster RJ, Heeley EL, Peiris DP, Bayram C, Cass A, Patel AA. Gaps in cardiovascular disease risk management in Australian general practice. Medical Journal Of Australia. 2009; 191(6): 324–9. DOI: 10.5694/j.1326-5377.2009.tb02816.x
Open DOI Search in Google Scholar Back to article
Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012. Journal of the American Heart Association. 2015; 4(4). DOI: 10.1161/JAHA.114.001709
Open DOI Search in Google Scholar Back to article
Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in vascular risk factor treatment and control in US stroke survivors: the National Health and Nutrition Examination Surveys (1999–2010). Circulation Cardiovascular quality and outcomes. 2013; 6(3): 270–7. DOI: 10.1161/CIRCOUTCOMES.113.000112
Open DOI Search in Google Scholar Back to article
World Health Organisation. Treatment of Tuberculosis Guidelines. Geneva: World Health Organization; 2010.
Search in Google Scholar Back to article
World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key population – 2016 update. Geneva: World Health Organization; 2016.
Search in Google Scholar Back to article
Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 368(9534): 505–10. DOI: 10.1016/S0140-6736(06)69158-7
Open DOI Search in Google Scholar Back to article
Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient preference and adherence. 2011; 5: 357–67. DOI: 10.2147/PPA.S22771
Open DOI Search in Google Scholar Back to article
Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient preference and adherence. 2010; 4: 115–25. DOI: 10.2147/PPA.S10330
Open DOI Search in Google Scholar Back to article
World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Geneva. 2002.
Search in Google Scholar Back to article
Munoz D, Uzoije P, Reynolds C, et al. Polypill for Cardiovascular Disease Prevention in an Underserved Population. N Engl J Med. 2019; 381(12): 1114–23. DOI: 10.1056/NEJMoa1815359
Open DOI Search in Google Scholar Back to article
Indian Polycap S, Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet. 2009; 373(9672): 1341–51. DOI: 10.1016/S0140-6736(09)60611-5
Open DOI Search in Google Scholar Back to article
Pill Collaborative Group, Rodgers A, Patel A, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One. 2011; 6(5): e19857. DOI: 10.1371/journal.pone.0019857
Open DOI Search in Google Scholar Back to article
Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. International journal of clinical practice. 2010; 64(9): 1220–7. DOI: 10.1111/j.1742-1241.2010.02412.x
Open DOI Search in Google Scholar Back to article
Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS ONE. 2012; 7(7): e41297. DOI: 10.1371/journal.pone.0041297
Open DOI Search in Google Scholar Back to article
Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): A pragmatic, cluster-randomised trial. Lancet. 2019; 394(10199): 672–83. DOI: 10.1016/S0140-6736(19)31791-X
Open DOI Search in Google Scholar Back to article
Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: Results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. Journal of the American College of Cardiology. 2014.
Search in Google Scholar Back to article
Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European journal of preventive cardiology. 2014. DOI: 10.1177/2047487314530382
Open DOI Search in Google Scholar Back to article
Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014; 348. DOI: 10.1136/bmj.g3318
Open DOI Search in Google Scholar Back to article
Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial. JAMA: the journal of the American Medical Association. 2013; 310(9): 918–29. DOI: 10.1001/jama.2013.277064
Open DOI Search in Google Scholar Back to article
Webster R, Patel A, Selak V, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. International journal of cardiology. 2016; 205: 147–56. DOI: 10.1016/j.ijcard.2015.12.015
Open DOI Search in Google Scholar Back to article
Selak V, Webster R. Polypills for the secondary prevention of cardiovascular disease: Effective in improving adherence but are they safe? Ther Adv Drug Saf. 2018; 9(2): 157–62. DOI: 10.1177/2042098617747836
Open DOI Search in Google Scholar Back to article
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension. 2010; 55(2): 399–407. DOI: 10.1161/HYPERTENSIONAHA.109.139816
Open DOI Search in Google Scholar Back to article
Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018; 15(6): e1002584. DOI: 10.1371/journal.pmed.1002584
Open DOI Search in Google Scholar Back to article
Webster R, Salam A, de Silva HA, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs. Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA: The journal of the American Medical Association. 2018; 320(6): 566–79. DOI: 10.1001/jama.2018.10359
Open DOI Search in Google Scholar Back to article
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2017. DOI: 10.22141/2307-1257.7.1.2018.122220
Open DOI Search in Google Scholar Back to article
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018; 39(33): 3021–104. DOI: 10.1093/eurheartj/ehy339
Open DOI Search in Google Scholar Back to article
Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: Health effects and costs. The Lancet. 2007; 370(9604): 2054–62. DOI: 10.1016/S0140-6736(07)61699-7
Open DOI Search in Google Scholar Back to article
World Health Organization. ‘Best buys’ and other recommended interventions for the prevention and control of non-communicable diseases. Tackling NCDs. Geneva; 2017.
Search in Google Scholar Back to article
World Health Organization. HEARTS: Technical package for cardiovascular disease management in primary health care. Geneva: World Health Organization; 2016.
Search in Google Scholar Back to article
Webster R, Castellano JM, Onuma OK. Putting polypills into practice: Challenges and lessons learned. Lancet. 2017; 389(10073): 1066–74. DOI: 10.1016/S0140-6736(17)30558-5
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.5334/gh.860 | Journal eISSN: 2211-8179

Journal RSS Feed

Language: English

Submitted on: Jul 6, 2020

Accepted on: Jul 27, 2020

Published on: Aug 19, 2020

Published by: Ubiquity Press

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

Cardiovascular Prevention,

© 2020 Ruth Webster, Adrianna Murphy, Helen Bygrave, Éimhín Ansbro, Diederick E. Grobbee, Pablo Perel, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 15 (2020): Issue 1